Skip to content
10-Q

Quarterly Report

ELITE PHARMACEUTICALS INC /NV/ ELTP

0001493152-26-007104

← back to feed
Filed
Feb 17, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · Feb 13, 2026 1.08B sh
Shares Diluted Q3 2026 · Dec 31, 2025 1.14B sh
Shares Diluted Q3 2026 · Dec 31, 2025 1.12B sh
Shares Diluted Q3 2026 · Dec 31, 2024 1.07B sh
Shares Diluted Q3 2026 · Dec 31, 2024 1.07B sh
Capex Q3 2026 · Dec 31, 2025 $527.61K
Capex Q3 2026 · Dec 31, 2024 $870.97K
Operating Cash Flow Q3 2026 · Dec 31, 2025 $14.6M
Operating Cash Flow Q3 2026 · Dec 31, 2024 $3.54M
Stockholders Equity Q3 2026 · Dec 31, 2025 $80.31M
Stockholders Equity Q3 2026 · Sep 30, 2025 $61.58M
Stockholders Equity Q3 2026 · Jun 30, 2025 $47.68M
Stockholders Equity Q3 2026 · Mar 31, 2025 $53.52M
Stockholders Equity Q3 2026 · Dec 31, 2024 $36.45M
Stockholders Equity Q3 2026 · Sep 30, 2024 $47.27M
Stockholders Equity Q3 2026 · Jun 30, 2024 $58.25M
Stockholders Equity Q3 2026 · Mar 31, 2024 $57.58M
Current Liabilities Q3 2026 · Dec 31, 2025 $13.19M
Current Liabilities Q3 2026 · Mar 31, 2025 $11.84M
Total Liabilities Q3 2026 · Dec 31, 2025 $46.1M
Total Liabilities Q3 2026 · Mar 31, 2025 $42.87M
Current Assets Q3 2026 · Dec 31, 2025 $96.79M
Current Assets Q3 2026 · Mar 31, 2025 $57.74M
Total Assets Q3 2026 · Dec 31, 2025 $126.41M
Total Assets Q3 2026 · Mar 31, 2025 $96.39M
Eps Diluted Q3 2026 · Dec 31, 2025 $0.01
Eps Diluted Q3 2026 · Dec 31, 2025 $0.02
Eps Diluted Q3 2026 · Dec 31, 2024 −$0.01
Eps Diluted Q3 2026 · Dec 31, 2024 −$0.02
Eps Basic Q3 2026 · Dec 31, 2025 $0.02
Eps Basic Q3 2026 · Dec 31, 2025 $0.02
Eps Basic Q3 2026 · Dec 31, 2024 −$0.01
Eps Basic Q3 2026 · Dec 31, 2024 −$0.02
Sga Expense Q3 2026 · Dec 31, 2025 $2.47M
Sga Expense Q3 2026 · Dec 31, 2025 $9.9M
Sga Expense Q3 2026 · Dec 31, 2024 $2.72M
Sga Expense Q3 2026 · Dec 31, 2024 $6.97M
Rd Expense Q3 2026 · Dec 31, 2025 $1.04M
Rd Expense Q3 2026 · Dec 31, 2025 $4.1M
Rd Expense Q3 2026 · Dec 31, 2024 $1.79M
Rd Expense Q3 2026 · Dec 31, 2024 $5.92M
Net Income Q3 2026 · Dec 31, 2025 $18.59M
Net Income Q3 2026 · Dec 31, 2025 $26.41M
Net Income Q3 2026 · Sep 30, 2025 $13.7M
Net Income Q3 2026 · Jun 30, 2025 −$5.88M
Net Income Q3 2026 · Dec 31, 2024 −$10.89M
Net Income Q3 2026 · Dec 31, 2024 −$21.31M
Net Income Q3 2026 · Sep 30, 2024 −$11.04M
Net Income Q3 2026 · Jun 30, 2024 $615.77K
Operating Income Q3 2026 · Dec 31, 2025 $9.01M
Operating Income Q3 2026 · Dec 31, 2025 $38.93M
Operating Income Q3 2026 · Dec 31, 2024 $1.1M
Operating Income Q3 2026 · Dec 31, 2024 $8.45M
Gross Profit Q3 2026 · Dec 31, 2025 $12.95M
Gross Profit Q3 2026 · Dec 31, 2025 $54.25M
Gross Profit Q3 2026 · Dec 31, 2024 $6.12M
Gross Profit Q3 2026 · Dec 31, 2024 $22.79M
Cost Of Revenue Q3 2026 · Dec 31, 2025 $18.64M
Cost Of Revenue Q3 2026 · Dec 31, 2025 $53.87M
Cost Of Revenue Q3 2026 · Dec 31, 2024 $8.24M
Cost Of Revenue Q3 2026 · Dec 31, 2024 $29.26M
Revenue Q3 2026 · Dec 31, 2025 $31.59M
Revenue Q3 2026 · Dec 31, 2025 $108.12M
Revenue Q3 2026 · Dec 31, 2024 $14.36M
Revenue Q3 2026 · Dec 31, 2024 $52.05M